With regard to the use of EGFR tyrosine kinase inhibitors given concurrently with TRT or CRT, the Cancer and Leukemia Group B30106 is a stratified phase II trial testing Gef concurrently with TRT alone or with CRT in patients with NSCLC (Ready et al, 2004), but the feasibility of Gef combined with CRT or TRT has not been established. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.